atenolol
/ Generic mfg.
- LARVOL DELTA
Home
Next
Prev
1 to 25
Of
1233
Go to page
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
May 28, 2025
Integrative Approaches in the Management of Hypertrophic Cardiomyopathy: A Comprehensive Review of Current Therapeutic Modalities.
(PubMed, Biomedicines)
- "Beta-blockers, including atenolol and nadolol, are considered the first-line treatment due to their ability to reduce heart rate and myocardial contractility and enhance diastolic filling. Non-dihydropyridine calcium channel blockers, such as verapamil and diltiazem, are utilized as second-line agents when beta-blockers are ineffective or contraindicated...Recent advancements in cardiac myosin modulators, such as Mavacamten and Aficamten, offer targeted therapies by modulating myosin-actin interactions to reduce LVOT gradients and improve symptoms, with promising results from clinical trials...Ultimately, the treatment and prevention of atrial fibrillation and sudden cardiac death are two key points of HCM management in both obstructive and non-obstructive forms. This review aims to provide an overview of current pharmacological and invasive strategies, as well as emerging therapies, in the management of HCM."
Journal • Review • Atrial Fibrillation • Cardiomyopathy • Cardiovascular • Gene Therapies • Hypertrophic Cardiomyopathy
May 26, 2025
Enhanced Removal of Common Wastewater-Derived Trace Organic Contaminants in Vertical-Flow Constructed Wetlands Amended with Fe(III)-EDTA.
(PubMed, ACS Environ Au)
- "Our results indicate that Fe-EDTA contributed to the degradation of carbamazepine and sulfamethoxazole under the studied flow regimes. The more readily degradable compounds atenolol and trimethoprim were removed with >97% efficiency in both control and amended columns, regardless of flow. This column study positively correlates Fe-EDTA with improved removal efficiencies of environmentally recalcitrant TrOCs without affecting readily degradable TrOCs."
Journal
May 26, 2025
Automatised online SPE-LC-MS/MS method for the enantioselective determination of chiral β-blockers and antidepressants in wastewater.
(PubMed, Anal Chim Acta)
- "In this work, an automatised method based on online solid phase extraction (SPE) coupled to liquid chromatography-tandem mass spectrometry (LC-MS/MS) was optimised and validated for the enantiomeric determination of highly prescribed (β-blockers (atenolol, metoprolol and propranolol), antidepressants (citalopram, fluoxetine, sertraline, duloxetine and venlafaxine) and two of their metabolites in influent and effluent wastewater. The method allows their automatised enantiomeric determination, including sample treatment, SPE column wash and conditioning, and LC-MS/MS determination, in 40 min with enantioresolution from 0.51 to 1.24. The online SPE method developed provides a fast way to obtain information about chiral compounds in wastewater reducing labour intensity, exposure to organic solvents, analyte loss and plastic waste."
Journal
May 26, 2025
A Langendorff-heart discovery pipeline demonstrates cardiomyocyte targeting by extracellular vesicles functionalized with beta-blockers using click-chemistry.
(PubMed, J Mol Cell Cardiol)
- "We tested this discovery pipeline by functionalizing EVs with beta-blockers (atenolol, metoprolol) using click-chemistry and incorporating the fluorescent protein NeonGreen2 to track the fate of EV cargo...Our findings demonstrate successful cardiomyocyte targeting using EVs decorated with beta-receptor binders. We propose the Langendorff-perfused heart as an intermediate step, nested between in vitro characterisation and animal testing, in discovery pipelines for seeking improved EV designs for the heart."
Journal
February 24, 2025
A Case of Beta Blocker and Calcium Blocker Overdose Managed With Veno-arterial Extracorporeal Circulation
(ATS 2025)
- "Case:A 40-year-old male presented to our hospital's emergency department after ingesting unknown quantities of metoprolol, diltiazem, and fluoxetine resulting in severe cardiogenic shock with bradycardia. The patient was treated with intravenous fluids, nor-epinephrine, epinephrine, dobutamine and placed on mechanical ventilation for supportive management of shock...CCB and more lipophilic BB such as propranolol are metabolized in the liver. The less lipophilic BB such as atenolol is excreted via the kidneys...This case adds to the limited literature on the use of VA ECMO as salvage therapy in severe cases of beta-blocker and calcium channel blocker overdose."
Clinical • Atrial Fibrillation • Cardiovascular • Fatigue • Hematological Disorders • Hypertension • Hypotension • Ischemic stroke • Metabolic Disorders • SLC51B
April 23, 2025
Clinical factors and prognostic outcomes of hyperthyroidism induced by immune checkpoint inhibitor therapy.
(ASCO 2025)
- "Inclusion criteria encompassed patients aged 18 years or older treated with ICIs (e.g., pembrolizumab, nivolumab, atezolizumab, cemiplimab) between January 1, 2013, and December 31, 2024. Patients with a history of thyroid disorders or Levothyroxine use were excluded...In patients with hyperthyroidism, 31.3% initiated metoprolol, 9.5% initiated propranolol, and 6.0% initiated atenolol for symptom management...Among all ICIs, atezolizumab (OR: 1.32; 95% CI: 0.82–2.13; p = 0.25) showed the strongest trend toward hyperthyroidism, followed by durvalumab (OR: 1.24; 95% CI: 0.75–2.05; p = 0.39), pembrolizumab (OR: 1.23; 95% CI: 0.81–1.87; p = 0.34), and nivolumab (OR: 1.22; 95% CI: 0.80–1.86; p = 0.37)... ICI-induced hyperthyroidism, while less common, has a significant impact on patient outcomes, including mortality. Identifying high-risk cancer subtypes and implementing proactive management, including beta-blocker therapy for symptom control, are critical steps to mitigate..."
Checkpoint inhibition • Clinical • Colon Cancer • Colorectal Cancer • Endocrine Disorders • Endometrial Cancer • Genito-urinary Cancer • Hematological Malignancies • Kidney Cancer • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Renal Cell Carcinoma • Solid Tumor
May 19, 2025
Case Report: High efficacy of low-dose flecainide as an add-on therapy to a beta-blocker for treating a high burden of idiopathic ventricular arrhythmias in a juvenile athlete.
(PubMed, Front Cardiovasc Med)
- "Initiation of treatment with atenolol 12.5 mg twice a day led to inadequate reduction of PVCs, with 29,452 isolated monomorphic PVCs (PVC burden: 29%) still observed on 24-h ambulatory electrocardiographic monitoring. The optimization of drug treatment was favored over catheter ablation since the athlete was a child and the probable origin of PVCs was the left ventricular outflow tract. This case report highlights that flecainide at a relatively low dose as an add-on therapy to a beta-blocker was highly effective and safe for treating high-burden PVCs originating from the ventricular outflow tract in a juvenile athlete."
Journal • Cardiomyopathy • Cardiovascular
May 19, 2025
Algae-driven bacterial production of extracellular reactive oxygen species for emerging contaminants degradation.
(PubMed, Sci Total Environ)
- "This study investigated the degradation of five ECs (carbamazepine, diclofenac, atenolol, sulfamethoxazole, and ofloxacin) by reactive oxygen species (ROS) generated through algal-bacterial interactions. Under ECs stress, the algal-bacterial system maintained cellular integrity and metabolic activity by upregulating pathways related to carbohydrate, lipid, amino acid, and nucleotide metabolism, thereby enhancing its resistance. These findings highlight the significant potential of algal-bacterial systems for the transformation of ECs, offering a sustainable strategy for bioremediation and the restoration of ecosystem health."
Journal
May 08, 2025
A Rare Cause of Hypergonadotropic Hypogonadism: H Syndrome
(ESPE-ESE 2025)
- "His current treatment includes methotrexate, tocilizumab, atenolol, hydrocortisone and tranexamic acid. Transitioning from paediatric to adult care poses additional challenges due to changing patient needs and a lack of literature on the condition. Early diagnosis is imperative to slow down disease progression and manage complications effectively."
Late-breaking abstract • Alopecia • Cardiomyopathy • Cardiovascular • Dermatology • Diabetes • Endocrine Disorders • Hematological Disorders • Hepatology • Hypertrophic Cardiomyopathy • Idiopathic Arthritis • Immunology • Metabolic Disorders • Nephrology • Otorhinolaryngology • Pediatrics • Rare Diseases • Renal Disease • Respiratory Diseases • Rheumatology • Sleep Apnea • Sleep Disorder • Type 1 Diabetes Mellitus
May 16, 2025
The Impact of Permeation Enhancers on Transcellular Permeation of Small Molecule Drugs.
(PubMed, J Phys Chem B)
- "This manuscript uses all-atom molecular dynamics (MD) simulations to showcase the effects of sodium caprate (C10) and salcaprozate sodium (SNAC), two commonly applied PEs, on membrane properties and the free energy profiles of five small molecule drugs (mannitol, atenolol, ketoprofen, decanedecaol, mucic acid)...The analysis of the MD simulations revealed that PEs make the membrane tail region more hydrophilic by forming hydrogen bonds with small molecule drugs, i.e., decreasing the central barrier of the permeation free energy. While this study was only limited to small molecule drugs, this lays the groundwork for future studies to which the effects of the PEs in the permeation of macromolecules and peptides may be observed."
Journal
May 13, 2025
Effect of Labetalol, Atenolol, and Nifedipine on Maternal Hemodynamics Measured by ICG in Early Pregnancy
(clinicaltrials.gov)
- P=N/A | N=60 | Recruiting | Sponsor: Marshall University | Trial completion date: Dec 2024 ➔ Dec 2025 | Trial primary completion date: Apr 2024 ➔ Dec 2025
Trial completion date • Trial primary completion date • Cardiovascular • Hypertension
April 10, 2025
Elevated Risk of Life-Threatening Metabolic Acidosis with Combined Metformin and SGLT2 Inhibitor Therapy in the Elderly
(ESPE-ESE 2025)
- "Her home medications included Dapagliflozin 5 mg (started 6 months ago), Metformin XR 500 mg BID (started 8 years ago), Amlodipine, Atenolol, Hydrochlorothiazide, Olmesartan, and Rosuvastatin. Although it is often challenging to identify the exact cause of lactic acidosis, her clinical picture raised suspicion of metformin-induced lactic acidosis due to the initial failure to respond to fluid resuscitation and pressors, followed by improvement after CRRT, and a negative work-up for infection and other causes. 3There is a similar case presenting severe euglycemic ketoacidosis and lactic acidosis in a diabetic patient on chronic Dapagliflozin and Metformin therapy, which was triggered by poor oral intake and dehydration, ultimately requiring dialysis. Our case underscores the caution needed when using a combination of metformin and SGLT-2 inhibitors, especially in elderly T2D patients with decreased GFR."
Clinical • Alzheimer's Disease • Cardiovascular • Chronic Kidney Disease • CNS Disorders • Dementia • Diabetes • Diabetic Nephropathy • Hypotension • Infectious Disease • Metabolic Disorders • Nephrology • Renal Disease • Type 2 Diabetes Mellitus
April 10, 2025
Hypertension Secondary to Primary Hyperaldosteronism
(ESPE-ESE 2025)
- "Despite being on optimized doses of four antihypertensive drugs, including two diuretics (amlodipine 10 mg, losartan 100 mg, chlorthalidone 50 mg, hydralazine 100 mg, and spironolactone 300 mg), his blood pressure remained poorly controlled...Spironolactone was discontinued, and the patient maintained control with atenolol, losartan, and a reduced dose of amlodipine (5 mg)...Early diagnosis and appropriate treatment of primary hyperaldosteronism not only optimize blood pressure control but also correct electrolyte imbalances and significantly reduce long- term cardiovascular risks. A multidisciplinary approach remains essential for achieving the best outcomes."
Brain Cancer • Cardiovascular • Cervical Cancer • Endocrine Cancer • Endocrine Disorders • Hypertension • Obstructive Sleep Apnea • Oncology • Respiratory Diseases • Sleep Apnea • Sleep Disorder • Solid Tumor
May 06, 2025
Cardiac physiological changes induced by cardiovascular drugs from different chemical classes in zebrafish mirrored in mice: A predictive tool for comprehensive risk assessment.
(PubMed, Indian J Pharmacol)
- "Our findings highlight the zebrafish model's utility for early-phase cardiac risk assessment in drug discovery due to its high throughput capabilities and other beneficial features."
Journal • Preclinical • Cardiovascular
April 27, 2025
Acute and Persistent Cardiovascular Effects of Menthol E-Cigarettes in Mice.
(PubMed, J Am Heart Assoc)
- "Exposure to menthol e-cigarette aerosols induces persistent cardiovascular autonomic imbalance in vivo. These findings raise the possibility of similar effects in humans using mentholated e-cigarettes."
Journal • Preclinical • Cardiomyopathy • Cardiovascular
April 27, 2025
Rheological Insight into the 3D Printability of Carboxymethyl Cellulose-Based Hydrogels.
(PubMed, Gels)
- "This study presents a comprehensive rheological analysis of the yielding and recovery properties critical for ensuring the printability of carboxymethyl cellulose (CMC)-based hydrogels incorporating atenolol, an antihypertensive agent, as the active ingredient...Additionally, the analysis of the Sequence of Physical Processes (SPP) during each deformation cycle provided deeper insight into oscillatory yielding behavior, emphasizing the role of elastic strains in determining printability. Overall, the study offers valuable understanding of the nonlinear viscoelastic behavior of CMC-based hydrogels, providing a framework for optimizing hydrogel formulations in DIW applications."
Journal
April 27, 2025
From Hashimoto's Thyroiditis to Graves' Disease: Autoimmune Thyroid Disease, a Dynamic Spectrum
(ENDO 2025)
- "TSH was then found to be consistently suppressed, even with weaning levothyroxine completely off...The patient was started on Methimazole for the treatment of GD and Atenolol for symptomatic management which helped improve symptoms...The patient was seen by an Oculoplastic specialist who started the patient on Teprotumumab for the treatment of severe thyroid eye disease... Autoimmune thyroid disorder is a spectrum with its dynamic nature stemming from the delicate balance of different characteristic antibodies. This case is a cardinal reminder of this, and it documents the rare but possible phenomenon of transitioning from a diagnosis of HT to GD. Furthermore, it underscores the importance of the close monitoring of thyroid studies and antibody profiles in patients with an autoimmune thyroid disease."
Endocrine Disorders • Grave’s Disease • Immunology • Ophthalmology • Thyroid Eye Disease
April 27, 2025
An Unusual Case of Catecholamine-Secreting Carotid Body Paraganglioma
(ENDO 2025)
- "She was started on doxazosin 2 mg and atenolol 25 mg oral daily for symptom control. HNPGLs are rarely associated with catecholamine hypersecretion. The prevalence of clinically significant catecholamine secreting HNPGLs has been estimated to be 7.7%–9.2%. However, this patient has bilateral carotid body PGLs with distinct metabolic activity."
Clinical • CNS Tumor • Cough • Endocrine Cancer • Endocrine Disorders • Gastrointestinal Disorder • Metabolic Disorders • Musculoskeletal Pain • Neuroendocrine Tumor • Oncology • Otorhinolaryngology • Pain • Respiratory Diseases • Solid Tumor • SYP
April 27, 2025
Graves' Disease and Thyrotoxic Periodic Paralysis: A Case Series
(ENDO 2025)
- "Following development of hypothyroidism, he was placed on levothyroxine replacement, with no further recurrence of paralysis.Case 2: An 18 y.o. Caucasian male with a history of Graves' disease presented after multiple hospitalizations for hypokalemia and lower extremity weakness...He was restarted on methimazole as well as atenolol and advised on medical adherence... These cases highlight the under recognition of TPP in non-Asian populations in the United States, leading to delayed diagnosis and recurrent hospitalizations. Clinicians should maintain a high index of suspicion for TPP in young males with hypokalemia, and generalized weakness, particularly in the setting of undiagnosed or untreated hyperthyroidism. Prompt recognition and definitive treatment of hyperthyroidism is critical to preventing recurrent episodes and associated morbidity.*."
Clinical • Endocrine Disorders • Grave’s Disease • Myositis
April 27, 2025
Elevated Risk of Life Threatening Metabolic Acidosis with Combined Metformin and SGLT2 Inhibitor Therapy in the Elderly
(ENDO 2025)
- "Her home medications included Dapagliflozin 5 mg (started 6 months ago), Metformin XR 500 mg BID (started 8 years ago), Amlodipine, Atenolol, Hydrochlorothiazide, Olmesartan, and Rosuvastatin. Although it is often challenging to identify the exact cause of lactic acidosis, her clinical picture raised suspicion of metformin-induced lactic acidosis due to the initial failure to respond to fluid resuscitation and pressors, followed by improvement after CRRT, and a negative work-up for infection and other causes.There is a similar case presenting severe euglycemic ketoacidosis and lactic acidosis in a diabetic patient on chronic Dapagliflozin and Metformin therapy, which was triggered by poor oral intake and dehydration, ultimately requiring dialysis. Our case underscores the caution needed when using a combination of metformin and SGLT-2 inhibitors, especially in elderly T2D patients with decreased*. .*"
Clinical • Alzheimer's Disease • Cardiovascular • Chronic Kidney Disease • CNS Disorders • Dementia • Diabetes • Diabetic Nephropathy • Hypotension • Infectious Disease • Metabolic Disorders • Nephrology • Renal Disease • Type 2 Diabetes Mellitus
April 02, 2025
Sotalol: A new alternative in medically-resistant pediatric POTS
(PAS 2025)
- "Patient 1 is an 18-year-old female with POTS that was treated with atenolol and fludrocortisone until she contracted COVID-19...Patient 3 is a 17-year-old female with POTS treated with metoprolol, midodrine, and ivabradine... All 3 patients were started on sotalol twice per day. This treatment provided heart rate control in these patients after they became treatment-resistant to other therapies following a viral infection or some unknown etiology. Sotalol caused an average decrease in heart rate of 98.7 bpm, and a standing heart rate of 100 bpm or less for all 3 patients, with remission of their tachycardia symptoms."
Clinical • Cardiovascular • Epstein-Barr Virus Infections • Genetic Disorders • Hypotension • Infectious Disease • Novel Coronavirus Disease • Pediatrics
April 16, 2025
Factors influencing nurses' knowledge and competence in warfarin-drug and nutrient interactions and patient counseling practices.
(PubMed, BMC Med Educ)
- "The study highlights significant gaps in nurses' knowledge of warfarin interactions, particularly with certain drugs and foods, and underscores the need for targeted education and training. However, the study is limited by its reliance on self-reported data and a convenience sampling approach, which may impact generalizability. Strengthening nurses' understanding of warfarin management, especially regarding high-risk interactions, is essential for improving patient safety and the efficacy of anticoagulant therapy. Future initiatives should focus on structured educational programs, introducing interactive e-learning modules, regular workshops, and case-based training, as well as promoting multidisciplinary teamwork to enhance nurses' competency in warfarin counseling and patient care."
Journal • Cardiovascular • Gastrointestinal Disorder
April 11, 2025
ABBV-712-induced cardiac pathology in rats is related to off-target-driven acute vasodilation, tachycardia, and increased cardiac contractility.
(PubMed, Toxicol Sci)
- "Telemetry-instrumented rats were administered ABBV-712 with or without atenolol to investigate effects of co-dosing on hemodynamic parameters and cardiac pathology. These effects were unrelated to TYK2 inhibition. This report is an example of a cross-functional mechanistic investigation into the pharmacologic cause of an identified cardiovascular toxicity."
Journal • Preclinical • Cardiovascular • Myocardial Infarction • TYK2
April 10, 2025
Efficacy of beta-blocker agents on clinical outcomes in patients with thoracic aortic aneurysm: A systematic review and meta-analysis of randomized controlled trials.
(PubMed, Vascul Pharmacol)
- "We found no evidence of benefit from β-blocker treatment for patients with TAA. More robust RCTs are needed to establish evidence-based recommendations."
Clinical data • Journal • Retrospective data • Cardiovascular • Genetic Disorders
January 28, 2025
A CASE REPORT OF SWALLOWING INDUCED ATRIAL TACHYCARDIA - Travis Hanson
(ACC 2025)
- "This 46-year-old male with palpitations, intermittent chest pain, and lightheadedness while swallowing was diagnosed with SIAT. The patient's symptoms have been well managed with metoprolol and diltiazem."
Case report • Clinical • Cardiovascular • Pain
1 to 25
Of
1233
Go to page
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50